Artiva Biotherapeutics Inc. Common Stock (ARTV)

FairStock Score: 31/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-Graham investor, I start with business quality and what I can count. Artiva is a clinical-stage biotech developing off-the-shelf NK-cell therapies, with lead candidate AlloNK for autoimmune diseases and cancers. It has no product revenue in the recent filings: fiscal Q2 2026, the quarter ended 2026-06-30, showed a net loss of $25.0M and diluted EPS of -$0.63, while fiscal 2025, the year ended 2025-12-31, showed a net loss of $83.9M on revenue N/A. The revenue history is thin and volatile: fiscal 2023 revenue was $32.9M, but fiscal 2024 revenue was only $251,000 and fiscal 2025 was N/A. I see no durable moat; value depends on clinical data and intellectual property. Financial health is mixed: debt/equity is just 0.03 and FairStock’s Altman Z-Score is 8.20, but trailing free cash flow is -$76.9M and FCF yield is -25.5%, while Piotroski is 2/9. At the 2026-10-26 close of $6.16, FairStock shows P/E -1.91, P/B 0.87, ROE -36.58%, ROCE -22.34%, and a FairStock Score of 31/100. The Lynch category is none because it lost money in each of the last three years. A low price-to-book may look tempting, but losses and cash burn make this a binary pipeline bet, not a classic Graham bargain.

In plain English: Artiva is a small healthcare company testing cell treatments for autoimmune diseases and cancer. It is not yet a proven business because it has no meaningful product sales and keeps losing money. At the $6.16 close on 2026-10-26, the shares look speculative rather than cheap: they trade below the accounting value of the company, but losses are large and the value depends mostly on future trial success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer